Literature DB >> 8228371

Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii.

R Berg1, P Bernasconi, D Fowler, M Gautreaux.   

Abstract

Microbial translocation is defined as the passage of viable microbes from the gastrointestinal (GI) tract to extraintestinal sites, such as the mesenteric lymph node (MLN), spleen, liver, kidneys, and blood. The ability of orally administered viable Saccharomyces boulardii to inhibit Candida albicans translocation from the GI tract was tested in antibiotic-decontaminated, specific pathogen-free (SPF) mice, which were orally challenged with C. albicans to promote intestinal overgrowth and subsequent translocation of this organism. Oral S. boulardii treatment reduced the incidence of MLN cultures positive for C. albicans but did not decrease the numbers of C. albicans per gram of MLN in these immunocompetent mice. Prednisolone immunosuppression increased translocation of C. albicans to the MLN and allowed translocating C. albicans to spread systemically to the spleen, liver, and kidneys. In these immunosuppressed mice, orally administered S. boulardii decreased both the incidence of C. albicans translocation to the MLN, liver, and kidneys and the number of translocating C. albicans per gram of MLN, spleen, and kidneys.

Entities:  

Mesh:

Year:  1993        PMID: 8228371     DOI: 10.1093/infdis/168.5.1314

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice.

Authors:  R D Wagner; C Pierson; T Warner; M Dohnalek; J Farmer; L Roberts; M Hilty; E Balish
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

2.  Effectiveness of bombesin and Saccharomyces boulardii against the translocation of Candida albicans in the digestive tract in immunosuppressed rats.

Authors:  Cem Algin; Adnan Sahin; Nuri Kiraz; Varol Sahintürk; Enver Ihtiyar
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

3.  Colonization of congenitally immunodeficient mice with probiotic bacteria.

Authors:  R D Wagner; T Warner; L Roberts; J Farmer; E Balish
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Uptake of yeast (Saccharomyces boulardii) in normal and rotavirus treated intestine.

Authors:  J Cartwright-Shamoon; G R Dickson; J Dodge; K E Carr
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

5.  Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.

Authors:  Laura Edwards-Ingram; Paul Gitsham; Nicola Burton; Geoff Warhurst; Ian Clarke; David Hoyle; Stephen G Oliver; Lubomira Stateva
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

6.  Intestinal candidiasis. A clinical report and comments about this opportunistic pathology.

Authors:  D Ruiz-Sánchez; L Calderón-Romero; J T Sánchez-Vega; J Tay
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

7.  Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism.

Authors:  J Y Malgoire; S Bertout; F Renaud; J M Bastide; M Mallié
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Disseminated infection with Saccharomyces kluyveri in a patient with AIDS.

Authors:  M Pynka; A Wnuk; D Bander; M Syczewska; A Boroń; B Prost; S Wrzecion
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

9.  Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation.

Authors:  S Thomas; I Przesdzing; D Metzke; J Schmitz; A Radbruch; D C Baumgart
Journal:  Clin Exp Immunol       Date:  2009-01-21       Impact factor: 4.330

10.  Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation.

Authors:  Anna Murzyn; Anna Krasowska; Piotr Stefanowicz; Dorota Dziadkowiec; Marcin Łukaszewicz
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.